At the heart of Ketel One Vodka lies one family’s unwavering passion for crafting the world’s finest spirits. Inspired by over 325 years of distilling expertise, the Nolet family brings old-world pot still craft and modern distilling techniques together in one flawless process. From Joannes to Jacobus to Carolus Sr., creator of Ketel One Vodka, to Carolus Jr. and Bob Nolet today, each of the 11 generations of Nolet family distillers is tasked with upholding a legacy of distilling excellence. Some may consider the Nolets a little obsessive, but those individuals just don’t understand. Everything must be done with meticulous attention to detail, because the family name is riding on every bottle of Ketel One Vodka.
“We take our work very seriously, not ourselves,” said Carl Nolet Jr., 11th Generation Nolet Family Distillery. “The stories we tell are all true and based on family events, beliefs and the pressure of upholding 11 generations of legacy for generations to come.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7975151-ketel-one-vodka
Employees and consumers are gaining greater influence over corporations' behavior thanks to a surge in e-commerce and social sharing, according to Sodexo's 2015 Workplace Trends Report, released today. A new form of public accountability, dubbed "Rateocracy," is putting unprecedented pressure on companies to act transparently, highlighting one of the major shifts in how the workplace is changing in response to technology and cultural expectations.
The report provides an in-depth analysis of nine notable implications accompanying this new era of Rateocracy, including the need for constant real-time reputation management and the new role of the CEO, which is to communicate an honest and aspirational vision that connects employees and consumers. Transparency is particularly important in addressing public relations challenges that are increasingly being amplified through social channels.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7065233-sodexo-workplace-trends-report/
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that many retina specialists throughout the U.S. are now using ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg to treat patients with diabetic macular edema (DME). The first injections of ILUVIEN in the U.S. were captured during a live web event attended by more than 250 eye care professionals. ILUVIEN is the first multiyear eye implant designed to deliver a continuous, submicrogram daily dose of steroid to the retina for 36 months with one injection. ILUVIEN is indicated for the treatment of DME in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure (IOP).
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7496251-iluvien-dme/
Wacom® today announces new Bamboo stylus products at IFA Berlin 2015. Leading the charge is the fine tip smart stylus for iPad: Bamboo®Fineline 2, a high-precision digital pen allowing creative thinkers to capture and shape their ideas.
“Our customer’s feedback drove the updates for our existing pen products,” Mike Gay, senior vice president of the consumer business unit at Wacom stated. “Wacom refined its pressure sensitive pen for the iPad to recreate the feel of writing with pen on paper. Bamboo Fineline 2 is the perfect complement to our Bamboo Paper app, allowing users to easily save, edit and share their work. Combined with the Wacom Cloud, this complete solution enables our customers to make their ideas a reality using their iPad.”
Bamboo Fineline 2’s improved industrial design provides a better writing experience and improved comfort. The battery for the Bamboo Fineline 2 lasts approximately 20 hours and is easily recharged via USB cable.
To view the multimedia release go to:
http://www.multivu.com/players/English/7613151-wacom-making-ideas-bamboo-fineline/
Booking.com, the world’s number one accommodation site, today announces the launch of the Booking Now app for the Apple Watch. Booking Now, which draws from Booking.com’s vast selection of over 625,000 properties in more than 75,000 unique destinations, is the first and only travel app to enable users to book a stay directly from their Watch, and in just one touch. Through the use of Apple’s new pressure sensitive ‘force touch’ technology, spontaneous travelers are now able to choose and book the nearest relevant hotel in one simple gesture.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7504251-booking-travel-app-for-apple-watch/
Cigna (NYSE: CI) today unveiled its new TV Doctors of America campaign to encourage people to improve their health by going for their annual check-up, knowing their biometric numbers for blood pressure, cholesterol, blood sugar and body mass index (BMI), and taking control of their health. Supporting Cigna’s effort are actors Patrick Dempsey, Donald Faison, Neil Patrick Harris and Kate Walsh. All four actors starred as doctors on TV and are striking doctor poses, donning scrubs and using their celebrity influence to shine a spotlight on preventive care and the importance of going to a real doctor for an annual check-up that can help save lives.
To view the multimedia release go to:
https://www.multivu.com/players/English/8163851-cigna-americas-tv-doctors-go-know-take-control/
Inspire Medical Systems, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Inspire Upper Airway Stimulation (UAS) therapy for use in a subset of patients with moderate to severe Obstructive Sleep Apnea (OSA) who are unable to use Continuous Positive Airway Pressure (CPAP). Inspire therapy is a fully implanted neurostimulation device, the first of its kind for sleep apnea, that provides an alternative treatment that is proven, convenient and easy to use.
To view the Multimedia News Release, go to: http://www.multivu.com/mnr/7169651-fda-approves-inspire-upper-airway-stimulation-therapy-sleep-apnea
HOME BLOOD PRESSURE MONITORS: https://amzn.to/2Yers09
THE HIGH BLOOD PRESSURE PROGRAM: https://bit.ly/2HR7gvw
BLOOD PRESSURE SUPPORT FORMULA:http://www.lnk123.com/SHwJN
High blood pressure during pregnancy can lead to serious, life threatening health issues for you or your baby. Watch this video which will tell you how to lower your blood pressure during pregnancy, your health depends on it!
EnteroMedics Inc. (NASDAQ: ETRM) today announced that the U.S. Food and Drug Administration (FDA) has approved VBLOC® vagal blocking therapy, delivered via the Maestro® System, for the treatment of adult patients with obesity who have a Body Mass Index (BMI) of at least 40 to 45 kg/m2, or a BMI of at least 35 to 39.9 kg/m2 with a related health condition such as high blood pressure or high cholesterol levels, and who have tried to lose weight in a supervised weight management program within the past five years. The Maestro System is the first new medical device to be approved by the FDA for obesity in over ten years. EnteroMedics anticipates that the device will be available, on a limited basis, at select Bariatric Centers of Excellence in the U.S. this year. The Maestro System has received CE Mark and is listed on the Australian Register of Therapeutic Goods.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7269351-enteromedics-fda-approval-vbloc-maestro-system-weight-loss-device/
Centennial College's Police Foundations program is a two-year program that consists of intense training equivalent to that of a paramilitary environment, which helps students to develop discipline and deportment. Courses are based on real-life experiences and case studies that incorporate a fundamental perspective on life. The program successfully prepares graduates for careers in the various police and military forces or in the field of security and related occupations and they have the ability to withstand pressure, communicate effectively, act as problem-solvers and help people in the community.
REMBRANDT®, the original at-home teeth whitening brand, enters the power toothbrush market for the first time with the launch of its power Whitening Toothbrush and Whitening Brush Heads, rounding out the brand’s suite of highly effective, scientifically proven teeth whitening solutions. The power toothbrush and 3-pack of replacement brush heads are now available online at Amazon.com and Rembrandt.com with a suggested retail price of $59.99 and $19.99 each, respectively.
REMBRANDT’S unique design features two brushing modes—Whitening and Sensitive—to allow consumers the ability to customize their daily whitening experience.
Based on in vitro laboratory testing, the REMBRANDT® Whitening Toothbrush and Brush Heads demonstrated seven times more plaque removal compared to a manual toothbrush. The rechargeable handle features a two-minute timer and a pressure sensor indicator to alert the user if they’re brushing too hard.
To view the multimedia release go to:
https://www.multivu.com/players/English/8240751-rembrandt-whitening-power-toothbrush/
Today, VSP Vision Care, the largest not-for-profit vision benefits provider in the United States, and market research agency YouGov released new findings showing that half of people in the U.S. are neglecting their eyes despite 84 percent of people rating vision as their most important sense. This disconnect occurs because people don’t understand the importance of annual eye exams and its connection to overall health.
In fact, only 1 percent of people know that signs of serious conditions like thyroid disease, high blood pressure, autoimmune disorders and certain types of cancer can be detected through annual eye exams. This is concerning because even if you have naturally good vision and don’t need prescription glasses, you still need an annual eye exam to protect your overall health.
To view the multimedia release go to:
https://www.multivu.com/players/English/8363551-vsp-vision-care/
